Biosimilar Monoclonal Antibodies Industry Research Report 2024
This report aims to provide a comprehensive presentation of the global market for Biosimilar Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Monoclonal Antibodies.
The Biosimilar Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Monoclonal Antibodies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Global markets are presented by Biosimilar Monoclonal Antibodies type, along with growth forecasts through 2030. Estimates on sales and revenue are based on the price in the supply chain at which the Biosimilar Monoclonal Antibodies are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2019-2024) and forecast period (2025-2030).
Biosimilar Monoclonal Antibodies segment by Type
This report has provided the market size (sales and revenue data) by application, during the historical period (2019-2024) and forecast period (2025-2030).
This report also outlines the market trends of each segment and consumer behaviors impacting the Biosimilar Monoclonal Antibodies market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Biosimilar Monoclonal Antibodies market.
Biosimilar Monoclonal Antibodies segment by Application
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2019-2030.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2023 because of the base year, with estimates for 2024 and forecast revenue for 2030.
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Biosimilar Monoclonal Antibodies market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Biosimilar Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Biosimilar Monoclonal Antibodies industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Monoclonal Antibodies.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biosimilar Monoclonal Antibodies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biosimilar Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
The Biosimilar Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Monoclonal Antibodies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Celltrion
- Pfizer (Hospira)
- 3SBIO
- Novartis (Sandoz)
- Dr Reddy’s
- Celgen Biopharma
- Cadila Healthcare
- Hisun Pharma
- Torrent Pharmaceuticals
Global markets are presented by Biosimilar Monoclonal Antibodies type, along with growth forecasts through 2030. Estimates on sales and revenue are based on the price in the supply chain at which the Biosimilar Monoclonal Antibodies are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2019-2024) and forecast period (2025-2030).
Biosimilar Monoclonal Antibodies segment by Type
- Infliximab
- Rituximab
- Trastuzumab
- Adalimumab
- Other
This report has provided the market size (sales and revenue data) by application, during the historical period (2019-2024) and forecast period (2025-2030).
This report also outlines the market trends of each segment and consumer behaviors impacting the Biosimilar Monoclonal Antibodies market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Biosimilar Monoclonal Antibodies market.
Biosimilar Monoclonal Antibodies segment by Application
- Oncology
- Autoimmune Disease
- Other
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2019-2030.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2023 because of the base year, with estimates for 2024 and forecast revenue for 2030.
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Biosimilar Monoclonal Antibodies market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Biosimilar Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Biosimilar Monoclonal Antibodies industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Monoclonal Antibodies.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biosimilar Monoclonal Antibodies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biosimilar Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Biosimilar Monoclonal Antibodies Market Size (2019-2030) & (US$ Million)
2.2.2 Global Biosimilar Monoclonal Antibodies Sales (2019-2030)
2.2.3 Global Biosimilar Monoclonal Antibodies Market Average Price (2019-2030)
2.3 Biosimilar Monoclonal Antibodies by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
1.2.2 Infliximab
1.2.3 Rituximab
1.2.4 Trastuzumab
1.2.5 Adalimumab
1.2.6 Other
2.4 Biosimilar Monoclonal Antibodies by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 Oncology
2.4.3 Autoimmune Disease
2.4.4 Other
3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
3.1 Global Biosimilar Monoclonal Antibodies Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Biosimilar Monoclonal Antibodies Sales (K Units) of Manufacturers (2019-2024)
3.3 Global Biosimilar Monoclonal Antibodies Revenue of Manufacturers (2019-2024)
3.4 Global Biosimilar Monoclonal Antibodies Average Price by Manufacturers (2019-2024)
3.5 Global Biosimilar Monoclonal Antibodies Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Biosimilar Monoclonal Antibodies, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Biosimilar Monoclonal Antibodies, Product Type & Application
3.8 Global Manufacturers of Biosimilar Monoclonal Antibodies, Date of Enter into This Industry
3.9 Global Biosimilar Monoclonal Antibodies Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 MANUFACTURERS PROFILED
4.1 Celltrion
4.1.1 Celltrion Company Information
4.1.2 Celltrion Business Overview
4.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
4.1.5 Celltrion Recent Developments
4.2 Pfizer (Hospira)
4.2.1 Pfizer (Hospira) Company Information
4.2.2 Pfizer (Hospira) Business Overview
4.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
4.2.5 Pfizer (Hospira) Recent Developments
4.3 3SBIO
4.3.1 3SBIO Company Information
4.3.2 3SBIO Business Overview
4.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
4.3.5 3SBIO Recent Developments
4.4 Novartis (Sandoz)
4.4.1 Novartis (Sandoz) Company Information
4.4.2 Novartis (Sandoz) Business Overview
4.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
4.4.5 Novartis (Sandoz) Recent Developments
4.5 Dr Reddy’s
4.5.1 Dr Reddy’s Company Information
4.5.2 Dr Reddy’s Business Overview
4.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
4.5.5 Dr Reddy’s Recent Developments
4.6 Celgen Biopharma
4.6.1 Celgen Biopharma Company Information
4.6.2 Celgen Biopharma Business Overview
4.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
4.6.5 Celgen Biopharma Recent Developments
4.7 Cadila Healthcare
4.7.1 Cadila Healthcare Company Information
4.7.2 Cadila Healthcare Business Overview
4.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
4.7.5 Cadila Healthcare Recent Developments
4.8 Hisun Pharma
4.8.1 Hisun Pharma Company Information
4.8.2 Hisun Pharma Business Overview
4.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
4.8.5 Hisun Pharma Recent Developments
4.9 Torrent Pharmaceuticals
4.9.1 Torrent Pharmaceuticals Company Information
4.9.2 Torrent Pharmaceuticals Business Overview
4.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
4.9.5 Torrent Pharmaceuticals Recent Developments
5 GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SCENARIO BY REGION
5.1 Global Biosimilar Monoclonal Antibodies Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Biosimilar Monoclonal Antibodies Sales by Region: 2019-2030
5.2.1 Global Biosimilar Monoclonal Antibodies Sales by Region: 2019-2024
5.2.2 Global Biosimilar Monoclonal Antibodies Sales by Region: 2025-2030
5.3 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2019-2030
5.3.1 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2019-2024
5.3.2 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2025-2030
5.4 North America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
5.4.1 North America Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
5.4.3 North America Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
5.5.1 Europe Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
5.5.3 Europe Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
5.6.1 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
5.6.3 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
5.7.1 Latin America Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
5.7.3 Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
5.8.1 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
5.8.3 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 SEGMENT BY TYPE
6.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2019-2030)
6.1.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2019-2030) & (K Units)
6.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2019-2030)
6.2 Global Biosimilar Monoclonal Antibodies Revenue by Type (2019-2030)
6.2.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2019-2030)
6.3 Global Biosimilar Monoclonal Antibodies Price by Type (2019-2030)
7 SEGMENT BY APPLICATION
7.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2019-2030)
7.1.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2019-2030) & (K Units)
7.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2019-2030)
7.2 Global Biosimilar Monoclonal Antibodies Revenue by Application (2019-2030)
6.2.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2019-2030) & (US$ Million)
6.2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
7.3 Global Biosimilar Monoclonal Antibodies Price by Application (2019-2030)
8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET
8.1 Biosimilar Monoclonal Antibodies Value Chain Analysis
8.1.1 Biosimilar Monoclonal Antibodies Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Biosimilar Monoclonal Antibodies Production Mode & Process
8.2 Biosimilar Monoclonal Antibodies Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Biosimilar Monoclonal Antibodies Distributors
8.2.3 Biosimilar Monoclonal Antibodies Customers
9 GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES ANALYZING MARKET DYNAMICS
9.1 Biosimilar Monoclonal Antibodies Industry Trends
9.2 Biosimilar Monoclonal Antibodies Industry Drivers
9.3 Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges
9.4 Biosimilar Monoclonal Antibodies Industry Restraints
10 REPORT CONCLUSION
11 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Biosimilar Monoclonal Antibodies Market Size (2019-2030) & (US$ Million)
2.2.2 Global Biosimilar Monoclonal Antibodies Sales (2019-2030)
2.2.3 Global Biosimilar Monoclonal Antibodies Market Average Price (2019-2030)
2.3 Biosimilar Monoclonal Antibodies by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
1.2.2 Infliximab
1.2.3 Rituximab
1.2.4 Trastuzumab
1.2.5 Adalimumab
1.2.6 Other
2.4 Biosimilar Monoclonal Antibodies by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 Oncology
2.4.3 Autoimmune Disease
2.4.4 Other
3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
3.1 Global Biosimilar Monoclonal Antibodies Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Biosimilar Monoclonal Antibodies Sales (K Units) of Manufacturers (2019-2024)
3.3 Global Biosimilar Monoclonal Antibodies Revenue of Manufacturers (2019-2024)
3.4 Global Biosimilar Monoclonal Antibodies Average Price by Manufacturers (2019-2024)
3.5 Global Biosimilar Monoclonal Antibodies Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Biosimilar Monoclonal Antibodies, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Biosimilar Monoclonal Antibodies, Product Type & Application
3.8 Global Manufacturers of Biosimilar Monoclonal Antibodies, Date of Enter into This Industry
3.9 Global Biosimilar Monoclonal Antibodies Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 MANUFACTURERS PROFILED
4.1 Celltrion
4.1.1 Celltrion Company Information
4.1.2 Celltrion Business Overview
4.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
4.1.5 Celltrion Recent Developments
4.2 Pfizer (Hospira)
4.2.1 Pfizer (Hospira) Company Information
4.2.2 Pfizer (Hospira) Business Overview
4.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
4.2.5 Pfizer (Hospira) Recent Developments
4.3 3SBIO
4.3.1 3SBIO Company Information
4.3.2 3SBIO Business Overview
4.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
4.3.5 3SBIO Recent Developments
4.4 Novartis (Sandoz)
4.4.1 Novartis (Sandoz) Company Information
4.4.2 Novartis (Sandoz) Business Overview
4.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
4.4.5 Novartis (Sandoz) Recent Developments
4.5 Dr Reddy’s
4.5.1 Dr Reddy’s Company Information
4.5.2 Dr Reddy’s Business Overview
4.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
4.5.5 Dr Reddy’s Recent Developments
4.6 Celgen Biopharma
4.6.1 Celgen Biopharma Company Information
4.6.2 Celgen Biopharma Business Overview
4.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
4.6.5 Celgen Biopharma Recent Developments
4.7 Cadila Healthcare
4.7.1 Cadila Healthcare Company Information
4.7.2 Cadila Healthcare Business Overview
4.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
4.7.5 Cadila Healthcare Recent Developments
4.8 Hisun Pharma
4.8.1 Hisun Pharma Company Information
4.8.2 Hisun Pharma Business Overview
4.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
4.8.5 Hisun Pharma Recent Developments
4.9 Torrent Pharmaceuticals
4.9.1 Torrent Pharmaceuticals Company Information
4.9.2 Torrent Pharmaceuticals Business Overview
4.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
4.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
4.9.5 Torrent Pharmaceuticals Recent Developments
5 GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SCENARIO BY REGION
5.1 Global Biosimilar Monoclonal Antibodies Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Biosimilar Monoclonal Antibodies Sales by Region: 2019-2030
5.2.1 Global Biosimilar Monoclonal Antibodies Sales by Region: 2019-2024
5.2.2 Global Biosimilar Monoclonal Antibodies Sales by Region: 2025-2030
5.3 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2019-2030
5.3.1 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2019-2024
5.3.2 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2025-2030
5.4 North America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
5.4.1 North America Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
5.4.3 North America Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
5.5.1 Europe Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
5.5.3 Europe Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
5.6.1 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
5.6.3 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
5.7.1 Latin America Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
5.7.3 Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
5.8.1 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
5.8.3 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 SEGMENT BY TYPE
6.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2019-2030)
6.1.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2019-2030) & (K Units)
6.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2019-2030)
6.2 Global Biosimilar Monoclonal Antibodies Revenue by Type (2019-2030)
6.2.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2019-2030)
6.3 Global Biosimilar Monoclonal Antibodies Price by Type (2019-2030)
7 SEGMENT BY APPLICATION
7.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2019-2030)
7.1.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2019-2030) & (K Units)
7.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2019-2030)
7.2 Global Biosimilar Monoclonal Antibodies Revenue by Application (2019-2030)
6.2.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2019-2030) & (US$ Million)
6.2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
7.3 Global Biosimilar Monoclonal Antibodies Price by Application (2019-2030)
8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET
8.1 Biosimilar Monoclonal Antibodies Value Chain Analysis
8.1.1 Biosimilar Monoclonal Antibodies Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Biosimilar Monoclonal Antibodies Production Mode & Process
8.2 Biosimilar Monoclonal Antibodies Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Biosimilar Monoclonal Antibodies Distributors
8.2.3 Biosimilar Monoclonal Antibodies Customers
9 GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES ANALYZING MARKET DYNAMICS
9.1 Biosimilar Monoclonal Antibodies Industry Trends
9.2 Biosimilar Monoclonal Antibodies Industry Drivers
9.3 Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges
9.4 Biosimilar Monoclonal Antibodies Industry Restraints
10 REPORT CONCLUSION
11 DISCLAIMER
